Bbva Compass Bancshares Inc. Trims Holdings in C.R. Bard, Inc. (BCR)
Bbva Compass Bancshares Inc. decreased its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 4.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,300 shares of the medical instruments supplier’s stock after selling 311 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in C.R. Bard were worth $2,340,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of BCR. Teachers Advisors LLC lifted its holdings in C.R. Bard by 5.7% during the 1st quarter. Teachers Advisors LLC now owns 142,186 shares of the medical instruments supplier’s stock worth $35,339,000 after buying an additional 7,705 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of C.R. Bard by 6.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 251,165 shares of the medical instruments supplier’s stock valued at $62,424,000 after acquiring an additional 15,240 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of C.R. Bard during the 1st quarter valued at $443,000. Caxton Associates LP bought a new stake in shares of C.R. Bard during the 1st quarter valued at $646,000. Finally, Bank of Nova Scotia raised its position in shares of C.R. Bard by 96.6% during the 1st quarter. Bank of Nova Scotia now owns 173,106 shares of the medical instruments supplier’s stock valued at $43,024,000 after acquiring an additional 85,042 shares during the last quarter. 79.27% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently commented on BCR shares. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. BidaskClub cut shares of C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. BMO Capital Markets restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. Finally, Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company. C.R. Bard has a consensus rating of “Hold” and an average target price of $292.00.
WARNING: “Bbva Compass Bancshares Inc. Trims Holdings in C.R. Bard, Inc. (BCR)” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/bbva-compass-bancshares-inc-trims-holdings-in-c-r-bard-inc-bcr/1675669.html.
C.R. Bard (NYSE:BCR) last posted its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.64 earnings per share.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. C.R. Bard’s payout ratio is presently 13.70%.
In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $327.31, for a total transaction of $1,094,524.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 136,568 shares of company stock valued at $43,932,079. 0.80% of the stock is currently owned by insiders.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.